ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Average Recommendation of “Buy” by Brokerages

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has been assigned a consensus recommendation of “Buy” from the four brokerages that are presently covering the firm, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a buy recommendation. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $80.00.

ANIP has been the subject of a number of analyst reports. Guggenheim reissued a “buy” rating and issued a $77.00 price objective on shares of ANI Pharmaceuticals in a research report on Tuesday, April 23rd. HC Wainwright lifted their price objective on shares of ANI Pharmaceuticals from $73.00 to $83.00 and gave the stock a “buy” rating in a research report on Monday, March 4th. Capital One Financial started coverage on shares of ANI Pharmaceuticals in a research report on Friday, March 15th. They issued an “overweight” rating and a $80.00 price objective on the stock. Finally, Truist Financial lifted their target price on shares of ANI Pharmaceuticals from $72.00 to $80.00 and gave the stock a “buy” rating in a report on Friday, March 1st.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, SVP James G. Marken sold 24,338 shares of ANI Pharmaceuticals stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $66.37, for a total value of $1,615,313.06. Following the completion of the sale, the senior vice president now owns 124,492 shares in the company, valued at approximately $8,262,534.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other ANI Pharmaceuticals news, SVP James G. Marken sold 24,338 shares of the firm’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $66.37, for a total transaction of $1,615,313.06. Following the transaction, the senior vice president now owns 124,492 shares in the company, valued at approximately $8,262,534.04. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Nikhil Lalwani sold 28,965 shares of ANI Pharmaceuticals stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $65.52, for a total value of $1,897,786.80. Following the completion of the transaction, the chief executive officer now directly owns 444,981 shares of the company’s stock, valued at $29,155,155.12. The disclosure for this sale can be found here. Insiders have sold 176,803 shares of company stock worth $11,695,866 in the last 90 days. Company insiders own 12.70% of the company’s stock.

Hedge Funds Weigh In On ANI Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. boosted its position in shares of ANI Pharmaceuticals by 93.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 513 shares of the specialty pharmaceutical company’s stock worth $30,000 after acquiring an additional 248 shares in the last quarter. BluePath Capital Management LLC bought a new stake in ANI Pharmaceuticals during the third quarter worth $34,000. Pacer Advisors Inc. acquired a new stake in shares of ANI Pharmaceuticals in the 4th quarter valued at $41,000. AJOVista LLC bought a new position in shares of ANI Pharmaceuticals in the 4th quarter valued at $58,000. Finally, SG Americas Securities LLC acquired a new position in shares of ANI Pharmaceuticals during the 1st quarter worth $106,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

ANI Pharmaceuticals Stock Performance

NASDAQ ANIP opened at $65.62 on Friday. The firm has a market cap of $1.38 billion, a price-to-earnings ratio of 78.12 and a beta of 0.80. The company has a current ratio of 3.57, a quick ratio of 2.81 and a debt-to-equity ratio of 0.66. ANI Pharmaceuticals has a 1-year low of $38.91 and a 1-year high of $70.81. The company has a 50 day moving average of $66.96 and a 200-day moving average of $59.36.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The firm had revenue of $131.65 million during the quarter, compared to analysts’ expectations of $123.02 million. ANI Pharmaceuticals had a return on equity of 18.06% and a net margin of 3.86%. On average, equities analysts forecast that ANI Pharmaceuticals will post 3.55 earnings per share for the current fiscal year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.